Kate Feldinger - Publications
Affiliations: | 2014-2017 | University of Oxford, Oxford, United Kingdom |
Year | Citation | Score | |||
---|---|---|---|---|---|
2019 | Valli A, Morotti M, Zois CE, Albers PK, Soga T, Feldinger K, Fischer R, Frejno M, McIntyre A, Bridges E, Haider S, Buffa FM, Baban D, Rodriguez M, Yanes O, et al. Adaptation to HIF1α deletion in hypoxic cancer cells by upregulation of GLUT14 and creatine metabolism. Molecular Cancer Research : McR. PMID 30885992 DOI: 10.1158/1541-7786.MCR-18-0315 | 0.496 | |||
2015 | Feldinger K, Kong A. Profile of neratinib and its potential in the treatment of breast cancer. Breast Cancer (Dove Medical Press). 7: 147-62. PMID 26089701 DOI: 10.2147/BCTT.S54414 | 0.636 | |||
2015 | Feldinger K, Kong A. Profile of neratinib and its potential in the treatment of breast cancer Breast Cancer: Targets and Therapy. 7: 147-162. DOI: 10.2147/BCTT.S54414 | 0.636 | |||
2014 | Feldinger K, Generali D, Kramer-Marek G, Gijsen M, Ng TB, Wong JH, Strina C, Cappelletti M, Andreis D, Li JL, Bridges E, Turley H, Leek R, Roxanis I, Capala J, et al. ADAM10 mediates trastuzumab resistance and is correlated with survival in HER2 positive breast cancer. Oncotarget. 5: 6633-46. PMID 24952873 | 0.521 | |||
2012 | Feldinger K, Kerry J, Gijsen M, Murphy G, Kong A. 86P The Role of Adam17 in Her2 Moderately Expressing Breast Cancer Annals of Oncology. 23: ii39. DOI: 10.1016/s0923-7534(19)65750-9 | 0.683 | |||
Show low-probability matches. |